Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(75.0%)

N/A

1(25.0%)

4Total

Phase 4(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06717191Phase 4Completed

Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan

Role: lead

NCT06674135Phase 4Completed

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

Role: lead

NCT06624943Phase 4Completed

Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali

Role: lead

NCT02017210Completed

Insulin-sensitive Obesity: Lessons From Longitudinal Data

Role: collaborator

NCT00168519Not ApplicableCompleted

Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

Role: collaborator

All 5 trials loaded